Key result
Patients with comorbid coronary artery disease and type 2 diabetes mellitus had higher blood levels of angiopoietin-2 compared to those with CAD without diabetes.
Why the study?
Comorbid coronary artery disease and type 2 diabetes mellitus worsen cardiovascular outcomes, but the role and clinical associations of the angiogenesis activator angiopoietin-2 in CAD patients with versus without diabetes remained to be examined.
Cross-Sectional (n=83)
No
Answers are grounded in this paper and cite their sources.
Angiopoietin-2 levels are significantly elevated in patients with both coronary artery disease and type 2 diabetes mellitus, suggesting its potential utility as a biomarker for assessing cardiovascular risk and inflammatory burden in this comorbid population.
Introduction. Coronary heart disease and type 2 diabetes mellitus are among the most common diseases of our time. Often existing as a comorbidity, they lead to the development of severe cardiovascular and renal complications, causing high mortality and disability of the population. These mutually aggravating diseases affect common target organs, which significantly increases the risk of cardiovascular complications and the frequency of macrovascular and microvascular disorders based on a combination of a number of pathogenetically significant factors (hyperglycemia; progressive insulin resistance with hyperinsulinemia and hypersympathicotonia, formation of endothelial dysfunction, activation of inflammation, etc.). In patients with type 2 diabetes mellitus, the risk of cardiovascular lesions of atherogenic origin and lethal outcomes as a consequence increases by 2 – 4 times compared to individuals without diabetes. Atherosclerotic lesions of the arteries in diabetes mellitus are predominantly diffuse and multiple with significant atherosclerotic changes in the proximal and distal parts of the vessels with an increased tendency for rupture of atherosclerotic plaques. The aim of this study was to examine the blood levels of the angiogenesis activator angiopoietin-2 (Angpt2) in patients with coronary artery disease and to determine its association with the clinical course of the disease, both in the presence and absence of diabetes mellitus. Materials and methods. The study included 61 patients with сoronary artery disease (39 men, 22 women) aged 40 to 72 years (mean age: 56.29 [43.0; 62.5] years). All patients were diagnosed with coronary artery disease (CAD) in the form of stable angina pectoris of functional class II. The study participants were divided into two groups: the main group, consisting of 31 patients with CAD and moderate type 2 diabetes mellitus, and the comparison group, which included 30 patients with CAD but without diabetes mellitus. Concomitant hypertension (grades 1–2) was identified in 15 patients, while heart failure (stage I–IIA, functional classes I–II) was diagnosed in 16 patients. Results. An analysis of lipid metabolism revealed that patients with comorbid coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) had significantly higher blood levels of triglycerides (p<0.01) and very low-density lipoprotein cholesterol (p<0.01) compared to patients with CAD without diabetes. As expected, patients with CAD and T2DM also exhibited a deterioration in carbohydrate metabolism, evidenced by a statistically significant increase in fasting glycemia (p<0.001), blood insulin concentration (p<0.05), and HOMA index (p<0.05) compared to those with CAD but without diabetes. Additionally, patients in the main group demonstrated elevated blood levels of high-sensitivity C-reactive protein (hs-CRP) compared to both healthy individuals and patients with CAD without diabetes, indicating a heightened inflammatory response. Conclusion. The study identified a significant increase in the blood levels of angiopoietin-2 (Angpt2), a potent proangiogenic and proarteriogenic factor with strong proinflammatory activity, in patients with CAD and T2DM compared to both healthy individuals and those with CAD without diabetes. These findings highlight the potential clinical value of measuring Angpt2 levels as part of a comprehensive assessment for patients with CAD and T2DM. Incorporating Angpt2 evaluation into routine diagnostics may enhance disease prognosis and improve treatment effectiveness.
No takes yet. Share an insight, caveat, or question.
Lytvynova et al. (2025) conducted a cross-sectional in Coronary Artery Disease and Type 2 Diabetes Mellitus (n=83). Type 2 Diabetes Mellitus vs. Coronary Artery Disease without Type 2 Diabetes Mellitus was evaluated on Blood levels of Angiopoietin-2 (Ang-2) in pg/ml (p=<0.001). Patients with comorbid coronary artery disease and type 2 diabetes mellitus had higher blood levels of angiopoietin-2 compared to those with CAD without diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: